MY207971A - Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates - Google Patents

Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates

Info

Publication number
MY207971A
MY207971A MYPI2022000293A MYPI2022000293A MY207971A MY 207971 A MY207971 A MY 207971A MY PI2022000293 A MYPI2022000293 A MY PI2022000293A MY PI2022000293 A MYPI2022000293 A MY PI2022000293A MY 207971 A MY207971 A MY 207971A
Authority
MY
Malaysia
Prior art keywords
serotypes
immunogenic composition
present
capsular polysaccharides
protein conjugates
Prior art date
Application number
MYPI2022000293A
Inventor
Soo Young Lee
Pan Kyeom Kim
Jun Won Chwa
Ji Hyoun Cha
Wan Geun La
Kyung Min Jo
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MY207971A publication Critical patent/MY207971A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an immunogenic composition including multivalent pneumococcal polysaccharide-protein conjugates. Each conjugate includes capsular polysaccharides of different pneumococcus serotypes conjugated to a carrier protein. More concretely, the present invention is a multivalent immunogenic composition including polysaccharide-protein conjugates. Each of the polysaccharide-protein conjugates includes Streptococcus pneumoniae-derived capsular polysaccharides of different serotypes conjugated to a carrier protein. The capsular polysaccharides include a) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and b) capsular polysaccharides of one or more serotypes selected from the group consisting of serotypes 10A, 11A, 15B, 22F, 23A, and 35B. The multivalent immunogenic composition according to the present invention is capable of inducing an immune reaction against a wider variety of serotypes than the conventional Prevenar 13. In particular, the conventional Prevenar 13 is designed mainly for serotypes frequently appearing in Europe and North America, but the immunogenic composition of the present invention is an immunogenic composition having high coverage not only in Europe and North America but also throughout Asia. Therefore, the multivalent immunogenic composition according to the present invention is capable of being beneficially used to prevent diseases caused by pneumococcus in infants, children, and adults. (Figure 1)
MYPI2022000293A 2019-07-18 2020-07-17 Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates MY207971A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190087004 2019-07-18
PCT/KR2020/009474 WO2021010798A1 (en) 2019-07-18 2020-07-17 Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
MY207971A true MY207971A (en) 2025-03-31

Family

ID=74211166

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022000293A MY207971A (en) 2019-07-18 2020-07-17 Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates

Country Status (8)

Country Link
JP (1) JP7441301B2 (en)
KR (1) KR20210010412A (en)
CN (1) CN114364397B (en)
AU (1) AU2020315673B2 (en)
MY (1) MY207971A (en)
PH (1) PH12022550133A1 (en)
TW (1) TWI864052B (en)
WO (1) WO2021010798A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019050814A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
ES3058336T3 (en) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Compositions comprising polysaccharide-protein conjugates of Streptococcus pneumoniae and methods of use thereof
CR20210333A (en) 2018-12-19 2021-08-18 Merck Sharp & Dohme COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND THEIR USE METHODS
KR20220102871A (en) * 2021-01-14 2022-07-21 (주)셀트리온 The immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate
GB2614916A (en) * 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
CN116942804A (en) * 2022-04-19 2023-10-27 上海瑞宙生物科技有限公司 Component of multivalent pneumococcal polysaccharide conjugate vaccine and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101515078B1 (en) * 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
PL3096786T3 (en) * 2014-01-21 2021-11-08 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CN104069504B (en) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 A method of enhancing polysaccharide protein conjugate immunogenicity
NZ752348A (en) * 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
CN110366428B (en) * 2016-12-30 2024-05-17 Vaxcyte公司 Polypeptide-antigen conjugates with unnatural amino acids
KR102101879B1 (en) * 2017-03-15 2020-05-29 주식회사 엘지화학 Multivalent vaccine composition against streptococcus
CN108079286B (en) * 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 13-valent pneumococcal polysaccharide-protein conjugate composition and preparation method and application thereof

Also Published As

Publication number Publication date
WO2021010798A1 (en) 2021-01-21
JP2022540718A (en) 2022-09-16
TWI864052B (en) 2024-12-01
CN114364397B (en) 2024-03-29
AU2020315673A1 (en) 2022-02-10
CN114364397A (en) 2022-04-15
PH12022550133A1 (en) 2022-11-14
JP7441301B2 (en) 2024-02-29
KR20210010412A (en) 2021-01-27
TW202116352A (en) 2021-05-01
AU2020315673B2 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
MY207971A (en) Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates
PH12020551147A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
PH12020551149A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
SA519401027B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ601711A (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
TW200719911A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
SA519401028B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2008079732A3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
SA517390539B1 (en) Multivalent Pneumococcal Conjugate Vaccine
NZ596500A (en) Pneumococcal polysaccharide conjugate vaccine
MX2009006548A (en) Multivalent pneumococcal polysaccharide-protein conjugate composition.
PH12015501269B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
EA202091440A1 (en) POLIVALENT ANTI-Pneumococcal POLYSACCHARIDE-PROTEIN CONJUGATED COMPOSITION
TW202617178A (en) Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
TH2201000264A (en) Immunogenic composition including a multivalent pneumococcal polysaccharide-protein conjugate.
EA201990131A1 (en) POLYVALENT Pneumococcal Polysaccharide-Protein Conjugate Composition
NZ775208B2 (en) Purified capsular polysaccharides of streptococcus pneumoniae
NZ775208A (en) Purified capsular polysaccharides of streptococcus pneumoniae
AR114442A1 (en) COMPOSITION OF THE PNEUMOCOCCAL MULTIVALENT PROTEIN-POLYSACCHARIDE CONJUGATE
AR114355A1 (en) COMPOSITION OF THE PNEUMOCOCCAL MULTIVALENT PROTEIN-POLYSACCHARIDE CONJUGATE